RESMED INC ($NYSE:RMD) reported their fiscal year 2023 fourth quarter earnings results on August 3 2023, for the period ending June 30 2023. All told, their total revenue increased 22.7% year over year to USD 1122.1 million, while net income was up 17.7%, totaling USD 229.7 million.
RESMED INC reported their fiscal year 2023 fourth quarter earnings on Thursday, June 30th 2023. The company’s stock opened at $220.6 and closed at $220.0, representing a 1.0% decrease in stock prices from the previous day’s closing price of $222.2. Analysts attributed the decrease in stock prices to company’s weak sales figures and poor guidance for the upcoming quarter. Despite this, RESMED INC’s net income for the quarter remained steady, and the company managed to exceed analyst expectations with its revenue figures.
They also reported that their expenses were lower than anticipated, which contributed to their overall profit. This was a positive sign for the company, as it indicated that their investments in research and development were paying off. Although RESMED INC’s stock dropped after the earnings report, overall investors remained optimistic about the company’s future performance. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Resmed Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Resmed Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Resmed Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Resmed Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Resmed Inc Intrinsic Value Calculator
We at GoodWhale conducted an in-depth analysis of RESMED INC‘s wellbeing. Our proprietary Valuation Line was used to calculate the fair value of RESMED INC’s share, which was determined to be around $265.6. Since then, however, the stock has been traded at $220.0, indicating that it is undervalued by 17.2%. In other words, the current market price of RESMED INC’s stock is actually lower than its fair value estimated by our Valuation Line. More…
Risk Rating Analysis
Star Chart Analysis
ResMed’s competitors include Natus Medical Inc, Sanara MedTech Inc, and Avita Corp.
As of 2022, Sanara MedTech Inc has a market cap of 227.36M and a Return on Equity of -22.91%. The company is a medical device company that develops and manufactures products for the treatment of chronic wounds and other conditions.
– Sanara MedTech Inc ($TPEX:4735)
Avita Corp is a biotechnology company that develops, manufactures, and markets products based on regenerative medicine. The company’s products are used to treat a variety of conditions, including burns, wounds, and skin diseases. Avita’s products are sold in over 30 countries worldwide. The company has a market cap of 1.21B as of 2022 and a return on equity of 9.62%.
Investors in ResMed Inc. have seen strong returns in the FY2023 Q4 results, with total revenue increasing 22.7% year-over-year and net income up 17.7%. This is a positive sign for investors, and indicates that ResMed Inc. is continuing to thrive in spite of the impacts of the pandemic. Moving forward, investors should watch the company’s financial performance and look for any signs of growth or progress. Despite the uncertain market conditions, ResMed Inc. is showing great promise and could be an attractive investment for the long term.